Overview
Marginal zone B-cell lymphoma (MZL) is a low-grade B-cell non-Hodgkin lymphoma that can arise in mucosa-associated lymphoid tissue (MALT), including Waldeyer's ring, characterized by extrafollicular growth patterns and diverse cellular compositions such as centrocyte-like cells and plasma cells 1.Diagnosis
Clinical Presentation: Often presents with bilateral palatine tonsil enlargement; history of chronic otitis media may be relevant 1.
Histopathology: Features include extrafollicular growth, marginal zone-like arrangement, and presence of centrocyte-like cells and plasma cells 1.
Differential Diagnosis: Differentiate from reactive lymphoproliferative disorders like chronic tonsillitis and infectious mononucleosis 1.
Immunophenotyping: Essential for confirming B-cell origin and identifying specific cell types 1.
Epithelial Tropism: Tumor cells often show tropism for the epithelium, a characteristic feature 1.
Imaging: Not specifically detailed in abstracts; typically supportive in assessing extent and local involvement 1.Management
First-Line Treatment: Rituximab monotherapy or in combination with chemotherapy (e.g., CHOP regimen) is often considered, though specific dosing details are not provided in the abstracts 1.
Localized Disease: Radiation therapy may be used for localized disease, particularly in cases not amenable to surgical resection 1.
Refractory or Recurrent Disease: Consideration of more aggressive regimens or clinical trials may be warranted 1.
Monitoring: Regular follow-up with imaging and biopsies to assess response and recurrence 1.Special Populations
Pediatrics: Not addressed in the provided abstracts 1.
Elderly: Management considerations similar to general population, with emphasis on tolerability and comorbidities 1.
Comorbidities: Presence of chronic otitis media noted in one case; management should consider these comorbidities 1.Key Recommendations
Histopathological Confirmation: Essential for diagnosing marginal zone B-cell lymphoma, distinguishing it from reactive conditions 1 (Evidence: Moderate).
Immunophenotyping: Required to confirm B-cell lineage and cellular subtypes 1 (Evidence: Moderate).
Consider Rituximab: First-line treatment option, either alone or in combination with chemotherapy, for managing MZL 1 (Evidence: Expert opinion).References
1 Kojima M, Nakamura S, Shuimizu K, Itoh H, Masawa N. Marginal zone B cell lymphomas of Waldeyer's ring--a report of two tonsillectomy cases resembling histomorphological features of inflammatory lesions. Pathology, research and practice 2001. link